Introduction
Schizotypal personality disorder (SPD) is classified in DSM-5 within the category of "Schizophrenia Spectrum and Other Psychotic Disorders," and is characterized by significant social deficits and discomfort, cognitive difficulties and perceptual disturbances, paranoia, and unusual behavior [1] . SPD shares genetic links with schizophrenia [2] and frequently clusters in families of individuals with schizophrenia [3] . The prevalence of SPD is estimated at approximately 3.9 % and is slightly more common among males than females [4] . SPD is highly comorbid with mood (44 %), anxiety (57 %), and substance use disorders (44 %), as well as with other personality disorders (83 %), particularly cluster B diagnoses [4] .
Individuals with SPD frequently manifest significant impairment in functioning: these persons often realize limited occupational status [5•, 6, 7] , reduced mental health, and social and emotional difficulties [4] . Cognitive deficits in this population are notable, particularly in working memory [8•] and context processing [9] . In imaging studies, these individuals display temporal lobe volume reductions similar to schizophrenia [10] , yet frontal lobe volume appears to be largely intact or increased [10, 11] . This has contributed to the hypothesis that compensatory frontal lobe functioning protects these individuals from the degree of psychosis and impairment seen in schizophrenia [3, 8•, 10] .
Patients typically present to psychiatric treatment with complaints of mood and anxiety symptoms rather than with concerns about cognitive, social and occupational functioning per se [1] . Literature regarding psychosocial and psychiatric treatment of this disorder is limited. However, in one treatment utilization study, patients with SPD were more likely to receive individual therapy, inpatient hospitalization, and treatment in a halfway house than those with a depression diagnosis [12] , likely reflecting the significant extent of functional impairment. Depressive symptoms are treated with antidepressant therapy and antipsychotics may also be prescribed for attendant psychotic-like symptoms. While there is no pharmacotherapy specifically indicated for the cognitive deficits of SPD and large-scale replication studies of investigational agents are needed, a trial of the α2a agonist guanfacine has shown promise as a cognitive enhancing agent [13] . Other mechanisms explored in preliminary studies include dopamine agonists [14, 15] and an anticholinesterase inhibitor [16] . Research on psychosocial interventions for SPD is scarce; however, cognitive remediation therapy (CRT) combined with social skills training for the cognitive and social deficits in this population is a promising avenue under investigation.
There are several excellent reviews of the etiology, and functional and cognitive impairment of SPD, which are outlined below in the section on References and Recommended Reading. -Employ memory aids such as planners, calendars and reminders.
-Some individuals find that development and maintenance of a structured schedule is helpful in improving cognitive function and managing symptoms. -Exercise has been shown to increase hippocampal volume in individuals with schizophrenia [17, Class II] as well as increase brain-derived neurotrophic factor (BDNF), a substance associated with neural plasticity [18] , which could facilitate learning and memory.
-Evidence suggests that malnutrition may be associated with reduced cognitive status and subsequent development of SPD traits [19] and as such, adequate nutrition is important. Omega-3 dietary supplements may be an additional area for research based on promising findings from the schizophrenia literature [20] . -Individuals with SPD may be encouraged to develop and access social outlets at community locations including libraries, religious centers, senior/community centers, etc. Some individuals may benefit from learning to test out paranoid assumptions and interpretations of others' behavior. This is likely to be most effective within the context of an ongoing therapeutic relationship with a mental health professional. -Significant comorbid mood and anxiety symptoms can directly affect cognitive performance and should be managed through psychosocial and/or pharmacological intervention (e.g., [21, Class IV] 
Emerging therapies
& There is preliminary evidence supporting further exploration of dopamine and α2a agonists as pharmacotherapies for cognitive deficits in SPD. All trials are investigational and no pharmacotherapies specifically for cognitive enhancement are used in routine clinical practice at this time.
α2 adrenergic agonists
Guanfacine
In a double-blind randomized trial of 29 patients with SPD, individuals receiving four weeks of the α2a agonist guanfacine demonstrated improvement in context processing, or the ability to accurately use previously presented information in behavioral responses [13, Class I].
Standard procedure Dosage was titrated to 2.0 mg/day. Standard procedure Patients in the active condition were titrated up to 0.3 mg/day.
Contraindications Cardiac valve problems
Complications/Special points During the course of this study, FDA approval for pergolide was revoked secondary to concerns about increased risk of valvular heart damage. This trial's enrollment was suspended due to safety concerns of ergot-derived dopamine agonists, although no participants experienced adverse events. 
Other treatments
Cognitive remediation therapy (CRT) is a behavioral intervention designed to improve cognition through repeated stimulation of areas important in cognitive functioning (see expert's workshop definition, [25] ). Treatment involves repeated and massed delivery of training exercises across a range of cognitive domains and is frequently delivered on the computer and in group formats. CRT is associated with positive cognitive and functional outcome in schizophrenia [26•] . CRT is frequently paired with a skills-training or a vocational rehabilitation group, with the goal of increasing real-world generalization of computer skills. The application of CRT to SPD is conceptually sound given its shared etiology and holds promise as a potential intervention for cognitive and functional deficits in SPD, but, as yet, there are no trials of effectiveness.
Cognitive remediation
Our group is currently testing a trial of cognitive remediation and social skills training in SPD. The trial is ongoing; however, preliminary results are promising in terms of participant tolerability and response.
Standard procedure In our experimental procedure, participants receive 7.5 weeks of twiceweekly computerized, coach-facilitated cognitive remediation treatment, plus concurrent social skills training. Computerized sessions employ Cognitive Enhancement Therapy [27] , and participants complete cognitive training exercises in small groups. Administration in small groups encourages additional opportunity for social skills practice, a particularly important exercise for this often socially isolated group of individuals. The addition of social skills training follows from schizophrenia research literature suggesting that transfer of learning is most salient when computer training is paired with a skills group [28] . In these groups, topics relevant to both cognitive difficulties (e.g., ways to enhance memory) and interpersonal issues (e.g., assessing and testing assumptions around nonverbal cues) are emphasized. We have developed our group curriculum based on the CET manual of Hogarty & Greenwald (2006), which is a companion to Psychological Software Services training sessions.
Contraindications Our group has not encountered any contraindications; cognitive training exercises are accessible, and even those individuals with limited computer facility can develop confidence and engage in the exercises.
Complications Group training may be an aversive activity to some individuals, particularly those presenting with significant paranoia and suspiciousness. In our experience, following a well-structured and explicit agenda in social skills training has been helpful in fostering comfort and reducing anxiety.
Special points We are also testing the addition of guanfacine to cognitive remediation to explore whether these two treatments are synergistic. In a small, randomized sample (n=8), the combined approach outperformed cognitive remediation alone in processing speed and problem solving (unpublished data), although replication is necessary.
Cost/cost-effectiveness Cognitive-remediation therapy is a relatively costly program. Participants attend treatment twice weekly and cognitive remediation coaching and social skills sessions are led by program staff. In addition, there are material costs of computers, space, and software.
Conclusion
Schizotypal personality disorder (SPD) is a personality disorder marked by substantial cognitive and social impairment. Individuals with this diagnosis demonstrate structural and cognitive deficits similar to those experienced by individuals with schizophrenia, have a high rate of psychiatric comorbidity, and typically realize reduced functioning. Cognitive deficits in areas such as working memory and context processing are notable and contribute to functional difficulties. Because some of the hallmark symptoms of this disorder are paranoia and social isolation, individuals with SPD may be reluctant to seek treatment for SPD symptoms; however, these individuals may present for co-occurring mood and anxiety symptoms. While there are no FDA-approved pharmacological agents used in routine clinical care for cognitive deficits experienced by patients with SPD, agents under investigation include α2a and dopamine agonists. Lifestyle modifications such as memory aids, exercise, and adequate diet may be helpful. Psychotherapeutic interventions include treating anxiety and depression, which may be exacerbating cognitive difficulties and encouraging increased social interaction for some patients. Additionally, cognitive remediation therapy plus social skills training, which has demonstrated benefits in schizophrenia, is a promising avenue currently under investigation.
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